Zai Lab to Participate in Investor Conferences in September 2025
PorAinvest
jueves, 28 de agosto de 2025, 7:34 am ET1 min de lectura
ZLAB--
At the Cantor Global Healthcare Conference, scheduled for Thursday, September 4, 2025, at 10:20 a.m. ET, members of Zai Lab's senior management team will deliver a presentation. The Morgan Stanley conference, set for Tuesday, September 9, 2025, at 2:35 p.m. ET, will feature a fireside chat with the company's leadership. Live webcasts of both events will be available on Zai Lab's Investor Relations page at ir.zailaboratory.com/webcasts-presentations, with archived replays accessible for up to 90 days following the events.
Zai Lab, based in China and the United States, is focused on discovering, developing, and commercializing innovative products that address unmet medical needs in oncology, immunology, neuroscience, and infectious disease. The company's portfolio includes several patented drug candidates, such as ZEJULA, OPTUNE, QINLOCK, NUZYRA, and VYVGART, among others.
This announcement follows Zai Lab's recent financial performance, where the company reported a narrowing loss in the first half of 2025, accompanied by a 15% increase in revenue [2].
References:
[1] https://www.stocktitan.net/news/ZLAB/zai-lab-announces-participation-in-investor-conferences-in-september-ujp2jo4end69.html
[2] https://www.marketscreener.com/news/zai-lab-s-loss-narrows-in-h1-as-revenue-jumps-15-ce7c50d8df88ff26
Zai Lab Limited will participate in investor conferences in September 2025, including the Cantor Global Healthcare Conference and Morgan Stanley 23rd Annual Global Healthcare Conference. Members of the company's senior management team will present at the events, and live webcasts will be available on the company's website. The conferences will focus on the company's research-based biopharmaceutical products in areas such as oncology, immunology, neuroscience, and infectious disease.
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a leading biopharmaceutical company, has announced its participation in two significant investor conferences in September 2025. The company will present at the Cantor Global Healthcare Conference and the Morgan Stanley 23rd Annual Global Healthcare Conference, both taking place in New York, NY.At the Cantor Global Healthcare Conference, scheduled for Thursday, September 4, 2025, at 10:20 a.m. ET, members of Zai Lab's senior management team will deliver a presentation. The Morgan Stanley conference, set for Tuesday, September 9, 2025, at 2:35 p.m. ET, will feature a fireside chat with the company's leadership. Live webcasts of both events will be available on Zai Lab's Investor Relations page at ir.zailaboratory.com/webcasts-presentations, with archived replays accessible for up to 90 days following the events.
Zai Lab, based in China and the United States, is focused on discovering, developing, and commercializing innovative products that address unmet medical needs in oncology, immunology, neuroscience, and infectious disease. The company's portfolio includes several patented drug candidates, such as ZEJULA, OPTUNE, QINLOCK, NUZYRA, and VYVGART, among others.
This announcement follows Zai Lab's recent financial performance, where the company reported a narrowing loss in the first half of 2025, accompanied by a 15% increase in revenue [2].
References:
[1] https://www.stocktitan.net/news/ZLAB/zai-lab-announces-participation-in-investor-conferences-in-september-ujp2jo4end69.html
[2] https://www.marketscreener.com/news/zai-lab-s-loss-narrows-in-h1-as-revenue-jumps-15-ce7c50d8df88ff26
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios